Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Nusinersen in Adult Patients with Spinal Muscular Atrophy
Neurol 95:e413-e416, Moshe-Lilie, O.,et al, 2020
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Low-Dose Aspirin and Risk of Intracranial Bleeds
Neurol 89:2280-2287, Soriano, L.C.,et al, 2017
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
An Observational Study of Thrombolysis Outcomes in Wake-Up Ischemic Stroke Patients
Stroke 44:427-431, Manawadu, D.,et al, 2013
Association between Guillain-Barr� Syndrome and Influenza a (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis
Lancet 381:1461-1468, Salmon, D.,et al, 2013
Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism
JAMA 309:1696-1703, Christensen, J.,et al, 2013
Elderly Patients are at Higher Risk for Poor Outcomes after Intra-Arterial Therapy
Stroke 43:2356-2361, Chandra, R.V.,et al, 2012
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Bleeding During Treatment with Aspirin Versus Apixaban in Patients with Atrial Fibrillation Unsuitable for Warfarin
Stroke 43:3291-3297, Flaker, G.,et al, 2012
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age
JNNP 82:712-717, Bhatnagar, P.,et al, 2011
Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy
NEJM 365:285-287, Egan, A.,et al, 2011
Treatment of Brain Arteriovenous Malformations
JAMA 306:2011-2019, Beijnum, J.V.,et al, 2011
A Systematic Review of Antiepilpetic Drug Initiation and Withdrawal
The Neurologist 15:122-131, Shih,J.J &Ochoa,J.G., 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Use of Antithrombotic Drugs and the Presence of Cerebral Microbleeds: The Rotterdam Scan Study
Arch Neurol 66:714-720,691, Vernooij,M.W.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Stroke 39:1482-1486,1406, Healey,J.S.,et al, 2008
Exposure to Antipsychotics and Risk of Stroke: Self Controlled Case Series Study
BMJ 337:616-618,586, Douglas,I.J. &Smeeth,L., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Multiple Ischemic Strokes Associated With Use of Recombinant Activated Factor VII
Arch Neurol 64:879-881, Libman,R.B.,et al, 2007
Adding Aspirin to Clopidogrel After TIA and Ischemic Stroke
Neurol 64:1117-1121, Hankey,G.J. &Eikelboom,J.W., 2005
Risk of Hemorrhagic Stroke With Aspirin Use
Stroke 36:1801-1807, Gorelick,P.B. &Weisman,S.M., 2005
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002
Tinzaparin in Acute Ischaemic Stroke (TAIST):A Randomised Aspirin-Controlled Trial
Lancet 358:702-710,683, Bath,P.M.W.,et al, 2001
Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events
ArchNeurol 57:326-332,306, Hart,R.G.,et al, 2000
Visual Field Constriction in Children Treated with Vigabatrin
Neurol 52:1713-1714,1537, Vanhatalo,S.&Paakkonen,L., 1999
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999